



January 28, 2026

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : *Intimation of Earnings Call to discuss the Unaudited Financial Results of HealthCare Global Enterprises Limited (“the Company”)*

Stock Code : *BSE – 539787, NSE – HCG*

Reference : *Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015*

Further to the intimation submitted to Stock Exchanges dated January 23, 2026, with respect to the meeting of the Board of Directors of the Company, to be held on Thursday, February 05, 2026, *inter-alia* to consider, approve and take on record the Unaudited Financial Results (both Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025 (“Unaudited Financial Results”), we would like to inform you that, an Earnings Conference Call has been scheduled on Monday, February 09, 2026, at 12.00 p.m. (IST), to discuss the Unaudited Financial Results of the Company.

You are requested to take the intimation on record.

Thanking you,
For **HealthCare Global Enterprises Limited**

Sunu Manuel
Company Secretary & Compliance Officer

Encl: a/a

HealthCare Global Enterprises Limited

HCG Tower, # 8, P Kalinga Rao Road, Sampangi Rama Nagar, Bangalore - 560027.

080 33669999 | info@hcgoncology.com | www.hcgoncology.com | CIN : L15200KA1998PLC023489



HEALTHCARE GLOBAL ENTERPRISES LIMITED

HCG's Q3 & 9M FY26 Earnings Call Monday, February 9, 2026 at 12 noon IST

Healthcare Global Enterprises Limited (HCG), India's leading provider of healthcare services, will organize a conference call for investors and analysts on **Monday, February 9, 2026 at 12 noon IST**.

The senior management of the Company will be present to address the call.

The conference call will be initiated with a brief management discussion on the Q3 & 9M FY26 results, to be declared on Thursday, February 5, 2026, followed by an interactive Question & Answer session.

Details of the conference call are as follows:

Timing : 12 noon IST on Monday, February 9, 2026

Pre-registration (Zero wait time to join the call) : *To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link:*



Conference dial-in Primary Numbers : +91 22 6280 1141 / +91 22 7115 8042

Hong Kong Toll Free Number : 800 964 448

Singapore Toll Free Number : 800 101 2045

UK Local Number : 0 808 101 1573

USA Local Number : 1 866 746 2133

About Healthcare Global Enterprises Limited (HCG):

HealthCare Global Enterprises Ltd. (++HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 22 comprehensive cancer centers across India and Africa, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof. Under the "Milann" brand, HCG operates 7 fertility centers.

For updates and specific queries, please visit www.hcgel.com or feel free to contact

Healthcare Global Enterprises Limited

investors@hcgoncology.com

CDR India

Anoop Poojari / Suraj Digawalekar

Ph.: +91 98330 90434 / 98211 94418

Email: anoop@cdr-india.com / suraj@cdr-india.com

Safe Harbor

This document may contain forward-looking statements about Healthcare Global Enterprises Limited and its Subsidiaries, which are based on the beliefs, opinions, and expectations of the company's management as the date of this Investor release and the companies do not assume any obligation to update their forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.